At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...

Scientists at Merck & Co. have unveiled the structure of the company’s latest candidate for HIV pre-exposure prophylaxis ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

Álvaro H. Borges, Andreas Lundh, Britta Tendal, John A. Bartlett, Nathan Clumeck, Dominique Costagliola, Eric S. Daar, Patrícia Echeverría, Magnus Gisslén, Tania B. Huedo-Medina, Michael D. Hughes, ...

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.

On June 5, 1981, national health experts published accounts of a strange infection circulating around Los Angeles. The U.S. Centers for Disease Control and Prevention (CDC) reported on that day that, ...

We performed a comparative study of detection of micrometastases using immunohistochemistry (IHC) by anti-cytokeratin antibody and carcinoembryonic antigen (CEA)-specific reverse-transcriptase ...